FDA grants accelerated approval to GSK's lung cancer drug
GSK•The FDA granted accelerated approval to GSK's drug for patients with advanced lung cancer whose disease progressed after earlier treatments.
1. Accelerated approval
The FDA granted accelerated approval to GSK's drug for patients with an advanced form of lung cancer whose disease has progressed after earlier treatments.




